Background. Pain is the most common presenting somatic s ymptom in medical outpatients,
Introduction
Pain is the most common sym ptom reported in both the general population and in prim ary care [1] . Pain complaints account for m ore than 40% of all symptom-related outpatient vis its and over 100 million ambulatory encounters in the U.S. each year [2] . In the United States alone, chronic pain conditions cost more than $500 billion annually in direct medical costs and lost productivity [1] . Pain m edications are the second most prescribed class of drugs (after cardiac-renal drugs), accounting for 12% of all medication prescribed during ambulatory office vis its in the United States [3] . Indeed, persistent pain is a major international health problem, prompting the World Health Organization to endorse a global cam paign against pain [4] .
Mus culoskeletal pain is consistently the m ost common, disabling, and costly of all pain complaints [5] . Indeed, two-thirds of pain-related outpatient visits are due to musculoskeletal pain, accounting for nearly 70 m illion outpatient visits in the U.S. each year [2] . In a s tudy assessing pain as the 5 th vital s ign in 9 Veteran Administration (VA) clinics, more than 80% of all pain complaints expressed by Veterans were musculoskeletal in nature [6] . Two Ins titute of Medicine reports have s ummarized the enormous functional and economic impact of m usculoskeletal pain on both the working and the retired population [1, 7] .
Depression and anxiety are the two most common mental health problems seen in the general medical setting, each being present in 10%-15% of primary care patients [8] [9] [10] .
They produce substantial disability and decrements in health-related quality of life, often exceeding the impairment seen in patients with chronic medical disorders [11, 12] .
Additionally, depression and anxiety each result in substantial health care costs as well as indirect costs due to lost work productivity [13, 14] .
Pain, anxiety, and depression are often inextricably linked (i.e., the PAD triad), such that disentanglement is scientifically and clinically impractical [15] [16] [17] . Moreover, PAD s ym ptoms have reciprocal negative effects on treatment response of one another, and additive adverse effects on health outcomes [18] [19] [20] . Thus, interventions that target the PAD
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Com prehensive vs . As s isted Management of Mood and Pain Symptoms (CAMMPS)
is a randomized comparative effectiveness trial comparing two pragmatic interventions (an intensive vs . a low-resource approach) for treating the pain plus anxiety and/or depression.
The assisted s ymptom management arm (ASM) intervention consists of automated symptom monitoring and prompted pain and mood s elf-management. The comprehensive symptom management (CSM) intervention combines ASM with optimized medication management and facilitated mental health care by a centralized nurse-physician team. The primary aim is to com pare the 12-month effectiveness of CSM vs . ASM in improving overall pain and mental health. Secondary outcomes will include health-related quality of life, disability, health care utilization, and treatment satisfaction.
Methods

Overview of Study Design and Research Aims and Hypotheses
CAMMPS is a 12-month randomized comparative effectiveness trial comparing a lowres ource entirely automated intervention to a m ore intense comprehensive intervention that com plements the automated intervention with a nurse-physician team collaborating with the prim ary care team through a largely telecare approach (i.e., most communication with patients and providers is by telephone or through secure e-mails and websites). Outcomes CAMMPS has one primary aim, two s econdary aims, and one exploratory aim.
Aim 1.
To com pare 12-month effectiveness of CSM vs. ASM in improving overall pain and mental health. Our hypothesis is that CSM will be superior to ASM in reducing a composite
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Aim 2.
To com pare 12-month effectiveness of CSM vs. ASM in improving specific PAD s ym ptoms. Our hypothesis is that CSM will be superior to ASM in reducing individual pain, anxiety, and depression scores.
Aim 3.
To com pare the effects of CSM vs . ASM on secondary outcomes, including healthrelated quality of life, disability, treatment satisfaction, and health care utilization.
Aim 4.
To explore patient-perceived barriers and facilitators of the CAMMPS intervention and the relative contribution of each intervention component to overall symptom improvement.
Conceptual Model
Figure 1 depicts the conceptual model underlying the CAMMPS trial. The ASM arm has 2 components that enhance usual care: automated PAD symptom monitoring and automated prompting of the patient to use pain and mood self-management strategies. The CSM arm adds 3 additional components to ASM: nurse contacts; optimized medication regimens for PAD s ym ptoms; and facilitated mental health care. Collectively, these 5 com ponents constitute the active intervention ingredients which may lead to an improvement in the primary (proximal) outcome, namely s ym ptom burden as measured by the composite PAD s ym ptom score. Secondary (distal) outcomes postulated to benefit from reduced PAD s ym ptom burden include health-related quality of life (HRQoL), disability, patient satisfaction, and health care utilization.
Eligibility
The s tudy population consists of Veterans 18 years and older receiving care from one Ps ychiatric comorbidity m ust meet any 1 of the following 3 criteria.
(1) Depression m ust be of at least m oderate severity, defined as a PHQ-8 score of 10 or greater with either depressed mood and/or anhedonia being endorsed. In previous s tudies, m ore than 90% of patients fulfilling this PHQ-8 criterion had major depression and/or dys thym ia, and the remaining patients had clinically significant depression with substantial functional impairment [24, 25] .
(2) Anxiety m ust be of at least moderate s everity, defined as a GAD-7 score of 10 or greater. In previous studies, the majority of patients fulfilling this GAD-7 criterion had one or more common DSM-IV anxiety dis orders (generalized anxiety, panic, social anxiety, and/or pos ttraumatic stress disorder), and the remaining patients had clinically significant anxiety with s ubstantial functional impairment [26, 27] . While the area under the curve is highest for generalized anxiety disorder (.91), it is also good for panic disorder (.85), social anxiety dis order (.83), and PTSD (.83). The positive likelihood ratio for a GAD-7 cutpoint of ≥ 10 for thes e 4 disorders is 5.1, 2.9, 3.6, and 3.5, respectively.
(3) Mixed anxiety-depression is defined as combined PHQ-8 and GAD-7 score ≥ 12.
Scores of 6 or higher on each scale represent at least mild depression or anxiety symptoms, res pectively [26] , and this level of s ymptoms has been shown responsive to treatment [28] .
Excluded are individuals who: (a) do not s peak English; (b) have moderately severe cognitive impairment as defined by a validated 6-item cognitive screener [29] ; (c) have s chizophrenia, bipolar disorder or other psychosis; (d) have a severe or complex mental illness or exhibit suicidal thoughts as their condition is unsuitable for a predominantly telecare intervention; (e) are pregnant; (f) have an anticipated life expectancy of less than 12 months.
Recruitment and Randomization
Phys icians working in the 5 primary care clinics were informed of the study in detail and were asked for permission to contact their patients for possible participation in the study.
Since this trial is a collaborative care intervention, only patients whose physicians provided Table 1 outlines the data collection protocol, including the variables that are measured, number of items, internal reliability (Cronbach's coefficient alpha) for scales, and tim e points for assessment. All assessments are conducted by a research assistant blinded to s tudy group.
Data Collection Protocol
Prim ary outcom e m easure
The primary outcome measure is the composite z-score of the main pain, anxiety and depression scales in this trial: the BPI, GAD-7, and PHQ-9, respectively. These 3 symptom s cales total 27 items: 11 items for pain, 7 for anxiety, and 9 for depression. Each of these measures has proven s ensitive to change in treatment trials [30] [31] [32] . The composite z-score
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As an im portant secondary outcome, a composite pain-anxiety-depression score from the PROMIS m easures (www.healthmeasures.net) will be calculated, using the 8 item scales for depression and anxiety and pain from the PROMIS-57 Profile [33] . Conversion tables allow direct conversion of simple s ummed raw s cores from PROMIS symptom scales into Ts core values. T-Score distributions are s tandardized such that a score of 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. A high score represents greater sym ptom severity. For example, a person who has a T-score of 60 is one standard deviation worse than the general population for the s ym ptom being measured. The composite PROMIS score will be the mean of the 3 symptom s cores; thus, a patient with PROMIS pain, anxiety and depression scores of 66, 58, and 53
would have a composite score of 59.
Other m easures
Clinical response is assessed for pain and mood using a 7-item patient-rated global change s cale (much better, moderately better, a little better, same, a little worse, moderately wors e, m uch worse) [34] . Three s econdary anxiety measures include the PTSD Checklist (PCL) to as sess the presence and severity of pos ttraumatic disorder [35] ; the Hopkins Sym ptom Checklist 10-item anxiety s cale [36] ; and the Mini-SPIN 3-item screener for social anxiety disorder [37] . items from the SF-36 were included which, along with items from the SF-12, provide the full SF-36 s ocial functioning, bodily pain, vitality and m ental health scales [40] . Patient-rated dis ability is assessed with the 3-item Sheehan Disability Scale [41] and a 2-item measure ACCEPTED MANUSCRIPT
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that as ks about the number of days in the past 4 weeks that the individual had to reduce activities by 50% or m ore for health-related reasons as well as percent effectiveness at work [23] . Additional scales include the 6-item pain catastrophizing scale from the Coping Strategies Questionnaire [42] ; the 5-item REMIT s cale which has shown to be useful in predicting depression remission [43] ; and the PROMIS 4-item scales for fatigue and sleep problems [44] , two sym ptoms that frequently co-occur with pain, anxiety and depression.
Medical comorbidity is assessed with a validated 9-disease checklist [45] . Substance us e is assessed with the AUDIT-C for alcohol [46] as well as questions about the use of tobacco, illicit drugs, and family history [23] . Health care utilization (outpatient visits, em ergency department vis its, and hospitalizations) and treatments (medications and nonpharmacological treatments specific to pain and mental health) are assessed using an interview coupled with electronic m edical review (EMR). Satisfaction with pain and mood treatm ents as well as the automated and nurse care manager components of the interventions are assessed with items used in previous trials [23, 25] . Three diagnostic variables were created: probable major depressive disorder using the PHQ-9 diagnostic algorithm [26] ; probable PTSD using a PTSD Checklist (PCL) score ≥ 41 [47] ; and substance us e risk derived from 13 items and categorized as low, intermediate, and high risk [23] . 
Assisted Sym ptom Managem ent (ASM) Intervention
Com prehensive Sym ptom Managem ent (CSM) Intervention
CSM Structure and Overview
This arm couples telecare management by a nurse-physician team with ASM, thus tes ting "combined" therapy vs . "monotherapy" (ASM only). As illustrated in our conceptual model (Figure 1) , the nurse provides several active components beyond ASM, including optimized medication management (analgesics and psychotropics) in conjunction with the s upervising physician, facilitated mental health care, and enhanced education, motivation, and coordination of care through periodic telephone contacts. CSM is intentionally tailored to each patient's specific PAD s ym ptoms, treatment preferences, and response to therapy; thus , frequency of nurse contacts as well as the s pecific content of nurse calls will necessarily vary with a "treat to target" approach [10] .
The nurse has scheduled telephone contacts with the patient at baseline, 1, 4, and 12 weeks, as well as sym ptom-triggered contacts based upon automated monitoring trend 
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Augmented Automated Sym ptom Monitoring for the CSM Arm
All patients randomized to the CSM arm receive the core ASM as described in section manager. Fourth, e-mail alerts are sent to the nurse to trigger patient calls for medication s ide effects, patient requests for treatment change or a nurse call, or missed ASM reports. 
Facilitated Mental Health Care
Optim ized Pharmacotherapy
The nurse care manager obtains a detailed history of current and past analgesic and psychotropic use as well as patient-recalled effectiveness and tolerability. Based upon this , the nurse-phys ician team develops an initial treatment plan based upon evidence-based medication algorithms used in previous trials [28, 48, 51] . Ps ychotropic medication is prescribed either by a mental health specialist or the prim ary care phys ician depending upon patient preferences (Figure 2 ). Due to their efficacy for both depression and anxiety, antidepressants are typically the preferred initial medication.
Thes e typically are either a s elective s erotonin reuptake inhibitor (SSRI), an SNRI, bupropion, or m irtazapine. Patients referred to psychiatry for more complex disorders (including PTSD) might receive a broader array of psychotropics based upon type of disorder and treatment response.
Duration of Intervention
This 12-month study is divided into 2 phases: (1) acute phase (first 6 months) during which automated sym ptom monitoring occurs weekly for the first month and then every other week during months 2 through 6 to allow careful follow-up of symptoms and treatment adjustments; (2) continuation phase (last 6 m onths) during which automated symptom monitoring occurs once a month to allow further treatment adjustments in subjects who fail to achieve target clinical responses during the acute phase or to detect relapse in subjects who 
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Determining Treatment Changes
The algorithm for determining treatment changes (Figure 3 
Statistical considerations 2.8.1. Sam ple size determination.
Sam ple size is determined to ensure adequate power for our primary hypothesis that CSM is s uperior to ASM in reducing composite PAD symptom severity. In our previous trials for depression [48, 49] . Since CAMMPS is com paring CSM to an active comparator ASM group rather than a usual care control group, we estimate a smaller effect size of 0.35, which is half way between a small (0.2) and moderate (0.5) effect size [54] . The primary outcome will be a composite pain-anxiety-depression score using the BPI, GAD-7, and PHQ-9 scores, res pectively. A s tandard z-s core will be calculated as the scale score minus the sample mean divided by the s ample standard deviation [55] . A composite pain-anxiety-depression s core will be the average of the s tandard z-s cores for the 3 scales. Since the z-score already is equal to the number of s tandard deviations, a between-group composite z-score difference of 0.35 is equivalent to an effect s ize of 0.35. Having 128 participants per treatment arm provides 80% power to detect a between-group effect size difference of 0.35 using a twos ample t-test with a 5% Type I error rate. Allowing for 15% attrition in our present trial, we initially projected a need for 150 per treatment arm, or a total of 300 participants. Two-thirds of the way through enrollment, the attrition was less than 10%, indicating that a sample size of 286 would be sufficient.
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Statistical analyses
All analys es will be based on intention-to-treat in all randomized participants. As the main test of our trial's treatment effect, we will evaluate the overall between-group differences on the composite pain-anxiety-depression z-score over the 12-month period of the trial using m ixed effects model repeated measures (MMRM) analysis [48, 49] .
Specifically, the com posite z-s core at 1, 3, 6, and 12 months will be used as the dependent variable in the m odel. Intervention group and dummy variables indicating the follow up time
(1, 3, 6 m onths, and 12 months) will be included as the main predictors. Baseline composite s core will be adjusted. A random intercept will be used to adjust for within-subject correlation.
Tim e-specific (1, 3, 6, and 12 m onths) between-group differences will also be compared. negative binomial distribution regression analysis will be used to model count data. For all s econdary outcomes, the p-values will be adjusted for multiplicity using the Sidak method [56] where: adjusted p-value = 1 -(1 -unadjusted p-value) # tests Analyses will be performed us ing SAS Vers ion 9.3.
Aim 4 will explore the independent effects of each of the 5 intervention components highlighted in the conceptual model ( Figure 1 ). Analyses for this aim will include only CSM participants since they received all 5 active components. The 5 components will be quantified as follows: 1) automated monitoring contacts (total number); 2) self-management modules com pleted (range, 0 to 9); 3) m edication changes (new analgesic and psychotropic starts and changes during the 12-month trial); 4) nurse contacts (total number); 5) mental health vis its (total number). Linear regression models will be run for each of the 5 components (in s eparate models and together) with the 12-month change in PAD composite score as the dependent variable and the specific components as predictor variables.
Qualitative interviews and analysis
A s ubsample of individuals completing their 12-month participation in the trial will be as ked if they are interested in being interviewed about their experience with the CAMMPS intervention, and those willing to participate will complete written informed consent.
Purposeful s ampling will be used to include participants from both CSM and ASM arms as well as those who were improved vs . s ame or worse on patient-reported global rating of change. As with previous s tudies, we expect thematic saturation to occur after interviewing 20 to 25 s tudy participants [57, 58] . An interview guide combining open-ended questions with a s eries of probing questions will be used to elicit perceived barriers and facilitators to key com ponents of the interventions. Audio recordings of the 30 to 60 minute interviews will be trans cribed, de-identified, and checked for accuracy. A team of analysts will use an im mersion-crystallization approach to analyze the qualitative data. Discrepancies will be
A C C E P T E D M A N U S C R I P T
res olved by consensus [59] . expressed potential interest in the study by returning a letter or calling a study phone num ber. Of the 1176 patients who completed an eligibility interview, 397 met study eligibility criteria. The most common reasons for not being eligible were pain or depression/anxiety s cores that were too low, or m ental health problems that were too complex for a telecare intervention. Of the 397 eligible patients, 294 (74%) enrolled in the study and were randomized to the CSM (n = 147) or ASM (n = 147) arms of the trial.
Results
Figure
Randomization resulted in comparable groups on all measured variables ( The m ean baseline BPI total pain s core was 5.9, with a mean BPI interference s core (n=38), 7 s ites by 9.2% (n=27), 8 to 9 s ites by 11.2% (n=33), and ≥ 10 sites by 4.8% (n=14).
There were no significant differences between the intervention and usual care groups in terms of duration of pain or the number of pain sites. Patients reported that they had to cut down on their usual activities for one-half day or m ore on 15.4 days in the past 4 weeks, and work effectiveness was only 61%. Multiple domains of health-related quality of life were also s ubstantially diminished.
Discussion
CAMMPS s uccessfully enrolled 294 primary care patients with chronic musculoskeletal pain and comorbid depression/anxiety, slightly exceeding the enrollment goal of 286 participants. Nearly three-fourths of eligible patients consented to participate, and randomization produced comparable intervention and control groups. The sample had moderately s evere levels of pain as well as depression and anxiety, and major depression and posttraumatic s tress disorder were each present in more than half of study participants.
Self-reported disability was s ubstantial, and there were major decrements in health-related quality of life.
CAMMPS focus es on patients with PAD com orbidity, i.e., those having pain plus anxiety and/or depression. Whereas most previous studies have focused on the PAD s ym ptoms individually, the high co-occurrence of these symptoms makes a monos ym ptomatic approach impractical as well as s ub-optimally effective. Single-condition care management programs are not only cos tly but tend to provide fragmented disease-based care rather than integrated management of the complex patient with comorbidity. In particular, pain is viewed by clinicians and patients alike as primarily a "medical" condition, whereas depression and anxiety are considered "mental" disorders. As a consequence, the management of pain and depression/anxiety too often gets carved up between the medical ACCEPTED MANUSCRIPT and m ental health components of the health care s ystem, rather than being integrated and coordinated.
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One lim itation of CAMMPS is the exclusively Veteran sample that was predominantly white m en who had a moderate degree of unemployment and financial constraints.
Moreover, the focus on patients with both chronic pain and psychiatric comorbidity resulted in relatively high rates of s elf-reported disability and functional impairment. However, if CAMMPS proves effective, the results may provide a conservative estimate of benefits given the com plex nature of both the patients' disorders as well as life circumstances. A second lim itation is the potential for selection bias arising from unmeasured differences between patients not responding to our mailed invitation and those we were able to contact by phone ( Figure 4 ). On the other hand, enrollment rates were high among those we were able to contact and who met s tudy eligibility criteria. Third, the multicomponent nature of the CAMMPS intervention m eans that the specific effects of individual components will be difficult to unbundle from the overall effects of the intervention. However, this is true for many com plex interventions for chronic disease [10, 60] , and our proposed exploratory analyses may at least partly is olate the relative contributions of specific components.
In s ummary, CAMMPS com pares a more resource-intensive intervention vs. a low- 
